The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

doi:10.1371/journal.pone.0109611

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

PloS one - 1 Jan 2014

Gámez-Pozo Angelo, Pérez Carrión Ramón M, Manso Luis, Crespo Carmen, Mendiola Cesar, López-Vacas Rocío, Berges-Soria Julia, López Isabel Álvarez, Margeli Mireia, Calero Juan L Bayo, Farre Xavier González, Santaballa Ana, Ciruelos Eva M, Afonso Ruth, Lao Juan, Catalán Gustavo, Gallego José V Álvarez, López José Miramón, Bofill Francisco J Salvador, Borrego Manuel Ruiz, Espinosa Enrique, Vara Juan A Fresno, Zamora Pilar

Abstract excerpt

BACKGROUND: Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression after trastuzumab treatment. METHODS: Data were collected from women with HER2-positive metastatic breast cancer treated with trastuzumab that experienced a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Phosphatidylinositol 3-Kinases

Share to Receptor, ErbB-2

Share to Survivors

Share to TOR Serine-Threonine Kinases

Share to Trastuzumab

Share to Treatment Failure

Source

Open in PubMed Open full text

Identifiers

PMID: 25330188
DOI: 10.1371/journal.pone.0109611
PMCID: PMC4203741

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.PMID 25330188Read ↗

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patientsSemantic proximity Read ↗

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer PatientsSemantic proximity Read ↗

A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast CancerSemantic proximity Read ↗

The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.Semantic proximity Read ↗

Genomic correlations for clinical outcomes in HER2-positive advanced gastric cancers treated using trastuzumab-based therapySemantic proximity Read ↗

Determining the Factors Predicting the Response to Anti-HER2 Therapy in HER2-Positive Breast Cancer PatientsSemantic proximity Read ↗

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity Read ↗

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity Read ↗

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.Semantic proximity Read ↗

Identification of markers to predict benefit from trastuzumab treatmentSemantic proximity Read ↗

Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity Read ↗

Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.